First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

26/03/2020 - 08:35

Marseille, France, March 26, 2020 – ImCheck Therapeutics announced today that it has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta (gd) T cell-activating monoclonal antibody (mAb) targeting the extracellular domain of Butyrophilin 3A (BTN3A), a member of the butyrophilin superfamily of immuno-modulatory targets. EVICTION (EValuation of ICT01 in Immuno-ONcology) is a first-in-human, two-part, open-label clinical trial to assess the safety, tolerability and activity of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced, relapsed/refractory cancer, including both solid and hematologic tumors that express BTN3A. The trial has been approved by regulators in France, Belgium, and Spain, with clinical trial applications pending or planned in the United Kingdom, Germany, and the United States. 

Read all news